Scientific Program – ANR 2025 – ADVANCES IN NEUROBLASTOMA RESEARCH MEETING

#ANR2025

Preliminary Scientific Program

Please click the button below to review the preliminary detailed scientific program .

Legend	Keynote Lecture	Plenary Sessions	Education Sessions
	Parallel Sessions	Rapid Fire Sessions	Poster Sessions
	Other Sessions	Sponsored Symposia	Social Events

08:30 – 08:45	Opening/Welcome ANR meeting
08:45 – 09:45	Plenary Session 1: Novel immune targets PHOX2B-directed peptide-centric CAR (PC-CAR) T cells show specificity and potent efficacy in preclinical models of high-risk neuroblastoma, *Muzamil Y Want, US* Targeting gangliosides in pediatric cancer, Guillermo N Dalton, US Safety and efficacy in a first-in-human GPC2 chimeric antigen receptor (CAR) T cell phase 1 trial for neuroblastoma,*Kristopher R. Bosse, US* Prevention of metastatic neuroblastoma using gene therapy to persistently express bispecific T-cell engaging diabodies, *Timothy P. Cripe, US*
09:45 – 10:30	*Keynote Lecture 1* Nucleoside-modified mRNA-LNP therapeutics *Drew Weissman, US*
10:30 – 11:00	Coffee Break
11:00 – 11:50	Parallel Session 1: Targets 2(transl) immune/other Ex vivo drug sensitivity profiling to complement molecular profiling in precision medicine for pediatric Neuroblastoma and other solid tumors, *Marlinde Celine Schoonbeek, Netherlands* Targeting lineage heterogeneity in neuroblastoma via cGAS-STING, Adam J Wolpaw, US Identification of canonical and non-canonical immunotherapeutic targets to overcome therapy-resistance in neuroblastoma, *Damon Hofman, Netherlands* ALCAM is a neuroblastoma oncoprotein and immunotherapeutic target, *Jarrett Lindsay, US* Prodrug-based therapy targeted to the norepinephrine transporter shrinks tumors and extends survival in models of recurrent ATRX-mutant neuroblastoma, *Michael Chorny, US*
11:50 – 14:10	Lunch Break & Poster Viewing Group A 12:20 – 13:05 Parent Advocate Session 13:15 – 14:00 Sponsored Symposium 1
14:10 – 15:10	Plenary Session 2: Profiling Longitudinal single-cell multiomic atlas of high-risk neuroblastoma reveals chemotherapy-induced tumor microenvironment rewiring, *Wenbao Yu, US* Spatial proteomics and single-cell RNA sequencing reveal subtype-specific immune interactions in neuroblastoma, *Joseph S. Toker, US* Proteomics of the neuroblastoma secretome reveals immunosuppressive factors inhibiting T cell responses, Judith Wienke, Netherlands Deciphering the neuroblastoma tumor microenvironment using spatial omics, Noah Bonine, Belgium
15:10 – 15:25	Rapid Fire Session 1 Imaging mass cytometry reveals the spatial network of immune cells in neuroblastoma, Francisca Bergsma, Netherlands Charting Adrenergic and Mesenchymal Interconversion Through In Vivo Single-Cell Barcoding RNA Sequencing in Neuroblastoma, *Stefano Di Giulio, US* Reconstructing evolution of high-risk neuroblastoma from single-nuclei DNA sequencing data, *Magdalena Seiffert, Germany* Survival of relapsed/refractory neuroblastoma patients treated with dinutuximab beta long term infusion depends on FC gamma receptor and NK cells, *Holger N Lode, Germany* Neuroblastoma in older children, adolescents and young adults: An updated report from the International Neuroblastoma Risk Group (INRG), Rebecca J. Deyell, Canada KIR ligand mismatched allogeneic cord blood transplantation reduces bone marrow relapse in high-risk neuroblastoma stage M, Shinsuke Kataoka, Japan Phase 1 Trial of universal donor NK cell infusions with temozolomide, irinotecan, and dinutuximab in patients with relapsed/refractory neuroblastoma, Keri A Streby, US A syngeneic MYCN-driven murine neuroblastoma allograft model for TCR mimetic CAR T cell preclinical therapeutics, *Elisabeth Posthill, US* An immunocompetent human B7H3 neuroblastoma mouse model for preclinical development of immunotherapies, *Thomas J Jackson, UK* A novel {MYCN}-driven mouse model to allow lineage tracing of neuroblastoma cells, *Lisa Werr, Germany*
15:25 – 15:55	Coffee Break
15:55 – 16:45	Parallel Session 3: Profiling (transl) The Genomic Landscape of Relapsed Neuroblastoma – What Comes Next? Pascal Kohmann, Germany Drug sensitivity profiling in the pediatric precision oncology program INFORM, *Ina Oehme, Germany* Single-cell study of bone marrow metastases reveals heterogeneity with paired primary tumor and subpopulations with therapy-resistant characteristics, Ilse Timmerman, Netherlands Spatial profiling of tumor cell states and their interaction with immune cells in high-risk neuroblastoma, Viktoria Humhal, Austria Genomic profiling in low and intermediate-risk neuroblastoma to refine treatment stratification and improve patient outcome. LINES: a SIOPEN trial, *Irene Jiménez, Spain*
16:45 – 18:15	Poster Session Group A
18:15 – 19:45	Welcome Reception

08:30 – 08:45	Opening/Welcome ANR meeting
08:45 – 09:45	Plenary Session 1: Novel immune targets PHOX2B-directed peptide-centric CAR (PC-CAR) T cells show specificity and potent efficacy in preclinical models of high-risk neuroblastoma, *Muzamil Y Want, US* Targeting gangliosides in pediatric cancer, Guillermo N Dalton, US Safety and efficacy in a first-in-human GPC2 chimeric antigen receptor (CAR) T cell phase 1 trial for neuroblastoma,*Kristopher R. Bosse, US* Prevention of metastatic neuroblastoma using gene therapy to persistently express bispecific T-cell engaging diabodies, *Timothy P. Cripe, US*
09:45 – 10:30	Keynote Lecture 1 Nucleoside-modified mRNA-LNP therapeutics *Drew Weissman, US*
10:30 – 11:00	Coffee Break
11:00 – 11:50	Parallel Session 2: GD2 Ab (Clin) Real-world data from SACHA-France on chemo-immunotherapy for relapsed high-risk neuroblastoma: predictive factors for outcome, Claudia Pasqualini, France Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab/GM-CSF in Relapsed and Refractory High-Risk Neuroblastoma, *Benjamin J. Lerman, US* Five-Year Outcome of High-risk Risk Neuroblastoma Patients Treated on NB2012, A Phase 2 Chemoimmunotherapy Induction Regimen with Hu14.18K322A, *Megan M Lilley, US* Respiratory Failure During Concomitant Lorlatinib, Sargramostim, and Dinutuximab Administration: Children’s Oncology Group (COG) ANBL1531 Experience, *Emily Greengard, US* Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta, Holger N. Lode, Germany
11:50 – 14:10	Lunch Break & Poster Viewing Group A 12:20 – 13:05 Parent Advocate Session 13:15 – 14:00 Sponsored Symposium 1
14:10 – 15:10	Plenary Session 2: Profiling Longitudinal single-cell multiomic atlas of high-risk neuroblastoma reveals chemotherapy-induced tumor microenvironment rewiring, *Wenbao Yu, US* Spatial proteomics and single-cell RNA sequencing reveal subtype-specific immune interactions in neuroblastoma, *Joseph S. Toker, US* Proteomics of the neuroblastoma secretome reveals immunosuppressive factors inhibiting T cell responses, Judith Wienke, Netherlands Deciphering the neuroblastoma tumor microenvironment using spatial omics, Noah Bonine, Belgium
15:10 – 15:25	Rapid Fire Session 1 Imaging mass cytometry reveals the spatial network of immune cells in neuroblastoma, Francisca Bergsma, Netherlands Charting Adrenergic and Mesenchymal Interconversion Through In Vivo Single-Cell Barcoding RNA Sequencing in Neuroblastoma, *Stefano Di Giulio, US* Reconstructing evolution of high-risk neuroblastoma from single-nuclei DNA sequencing data, *Magdalena Seiffert, Germany* Survival of relapsed/refractory neuroblastoma patients treated with dinutuximab beta long term infusion depends on FC gamma receptor and NK cells, *Holger N Lode, Germany* Neuroblastoma in older children, adolescents and young adults: An updated report from the International Neuroblastoma Risk Group (INRG), Rebecca J. Deyell, Canada KIR ligand mismatched allogeneic cord blood transplantation reduces bone marrow relapse in high-risk neuroblastoma stage M, Shinsuke Kataoka, Japan Phase 1 Trial of universal donor NK cell infusions with temozolomide, irinotecan, and dinutuximab in patients with relapsed/refractory neuroblastoma, Keri A Streby, US A syngeneic MYCN-driven murine neuroblastoma allograft model for TCR mimetic CAR T cell preclinical therapeutics, *Elisabeth Posthill, US* An immunocompetent human B7H3 neuroblastoma mouse model for preclinical development of immunotherapies, *Thomas J Jackson, UK* A novel {MYCN}-driven mouse model to allow lineage tracing of neuroblastoma cells, *Lisa Werr, Germany*
15:25 – 15:55	Coffee Break
15:55 – 16:45	Parallel Session 4: Immune 1 (transl) Adrenergic/Mesenchymal Plasticity Drives STING Suppression and Immune Escape in Neuroblastoma, *Stefano Di Giulio, US* The NK cell ligand MICA represents a lineage-specific immunogenic vulnerability in neuroblastoma, *Satyaki Sengupta, US* Anti-tumor efficacy of allogeneic O-Acetyl GD2-CAR NK cells against neuroblastoma, *Alice L Yu, US* Secreted T cell engagers directed against PTK7 enhance the potency of allogeneic γδ T cell therapy for neuroblastoma, *Hunter C. Jonus, US* Combining CD47 blockade with chemoimmunotherapy in preclinical chemoresistant neuroblastoma models, *Courtney Himsworth, UK*
16:45 – 18:15	Poster Session Group A
18:15 – 19:45	Welcome Reception

08:30 – 08:45	Opening/Welcome ANR meeting
08:45 – 10:30	Nursing Symposium
10:30 – 11:00	Coffee Break
11:00 – 11:50	Nursing Symposium (continue)
14:10 – 15:25	Nursing Symposium (continue)
15:25 – 15:55	Coffee Break
16:45 – 18:15	Poster Session Group A
18:15 – 19:45	Welcome Reception

08:00 – 08:45	Education Session 1: Neuroblastoma Sara Federico
08:45 – 09:00	Comfort Break
09:00 – 10:00	Plenary Session 3: Liquid Biopsy Investigation of tumor evolution mechanisms in high-risk neuroblastoma patients using liquid biopsy: A report from the Children’s Oncology Group,Gabriela Virdzekova, US Sequential cell free DNA analysis reveals genetic heterogeneity in patients with relapsed neuroblastoma enrolled in the SIOPEN-ITCC BEACON study,*Gudrun Schleiermacher, France* Multi-Omics profiling of neuroblastoma identifies immunological biomarkers associated with higher risk of relapse: results from the MICCHADO study,*Antonio Colaprico, France* Immune evasion and therapy resistance in neuroblastoma bone marrow metastasis, *SaraWernig Zorc,Austria*
10:00 – 10:45	Keynote Lecture 2 Poverty as a “Druggable” Target: A Framework for Oncology Health Equity Research *Kira Bona, US*
10:45 – 11:15	Coffee Break
11:15 – 12:05	Parallel Session 5: TERT (Basic) Characterising the spatial landscape of neuroblastoma using spatially resolved transcriptomics, *Pravin Velmurugan, Germany* NK cells mediate tumor immune evasion in bone marrow metastasis via the ALCAM-CD6 axis in {ATRX}-mutated neuroblastoma, *Magdalena Rados, Austria* Targetable Genetic Alterations in High-Risk Neuroblastoma Patients Enrolled in the SIOPEN HR-NBL1 Study,*Angela Bellini, France* Telomere maintenance mechanism and its associated genetic abnormalities in 321 neuroblastic tumors (A report from JCCG-JNBSG), *Miki Ohira, Japan* Clinical Significance of {TERT} Promoter Mutations in Neuroblastoma,Shakeel Modak, US
12:05 – 14:05	Lunch Break & Poster Viewing Group B
14:05 – 15:05	*Plenary Session 4: Clinical trials* Clinicobiological treatment stratification leads to excellent prognosis in MYCN-NA disseminated NB patients ≤12 months. Results of SIOPEN-LINES trial, *Irene Jiménez, Spain* Long term infusion of dinutuximab beta is associated with a survival advantage over short term infusion. Results from the HR-NBL1/SIOPEN trial, *Holger N Lode, Germany* Complete primary tumor resection is associated with improved outcomes in patients with high-risk neuroblastoma treated on COG ANBL0532, *Christa N Grant, US* Elucidating the B cell mediated anti-tumor immune response in neuroblastoma with opsoclonus myoclonus ataxia syndrome, *Matthias Fischer, Germany*
15:05 – 15:20	Rapid Fire Session 2 MYCN overexpression biases human sympatho-adrenergic development towards progenitor cells causing neuroblastoma-like tumor xenografts, Stéphane Van Haver, US Proteomic insights into extracellular vesicles in neuroblastoma biology, *Martin Auber, Germany* Mechanisms of extracellular vesicles-mediated neuroblastoma metastasis, Vladimir S. Spiegelman, US Administration of Intracerebroventricular Dinutuximab in the Treatment of CNS Neuroblastoma and Determination of CSF Pharmacokinetics, *Michael Migotsky, US* Survival Outcomes in Patients with High-Risk Neuroblastoma on Eflornithine (DFMO) Maintenance: Matched External Control Analysis at 7-Year Follow-Up, *William Ferguson, US* Inferring the evolution of structural genomic alterations in neuroblastoma by linked-read whole-genome sequencing, *Christoph Bartenhagen, Germany* Dinutuximab administration during Induction does not increase the development of HACA during Post-Consolidation, a report from COG ANBL17P1, *Ankita Shahi, US* Potential therapeutic targets for ATRX-aberrant neuroblastoma revealed by genome-wide CRISPR-Cas9 synthetic lethality screens, *Fenja L. Fahrig, Netherlands* Functional profiling on {ex vivo} neuroblastoma models: global collaboration to drive implementation in precision medicine, *Eleonora Jacoba Looze, Netherlands* Optimized Syngeneic Neuroblastoma Models to Advance Cell Therapies, *Ying Wang, US*
15:20 – 15:50	Coffee Break
15:50 – 16:40	Parallel Session 8: Immune 2 (transl) Identification of GDNF family receptor alpha 2 (GFRA2) as an immunotherapy target for neuroblastoma central nervous system (CNS) metastases, *Benjamin Lowry, US* GFRA2 as a candidate immunotherapeutic target in neuroblastoma and Ewing Sarcoma, Amber K Hamilton, US Preclinical Development of Chimeric TGFB Switch Receptor (CTSR)-Armored B7H3 CAR-T Cells for Neuroblastoma, *Babak Moghimi, US* VLA-4 targeted radiopharmaceutical therapy enhances CAR T-cell efficacy in pre-clinical models of neuroblastoma, *Constanza Rodriguez, US* Distinct subpopulations of cancer-associated fibroblasts (CAFs) drive neuroblastoma (NB) progression and drug resistance, *Kevin Louault, US*
16:40 – 18:10	Poster Session Group B
18:10 – 19:40	Young Investigator Reception

08:00 – 08:45	Education Session 1: Neuroblastoma Sara Federico
08:45 – 09:00	Comfort Break
09:00 – 10:00	Plenary Session 3: Liquid Biopsy Investigation of tumor evolution mechanisms in high-risk neuroblastoma patients using liquid biopsy: A report from the Children’s Oncology Group,Gabriela Virdzekova, US Sequential cell free DNA analysis reveals genetic heterogeneity in patients with relapsed neuroblastoma enrolled in the SIOPEN-ITCC BEACON study,*Gudrun Schleiermacher, France* Multi-Omics profiling of neuroblastoma identifies immunological biomarkers associated with higher risk of relapse: results from the MICCHADO study,*Antonio Colaprico, France* Immune evasion and therapy resistance in neuroblastoma bone marrow metastasis, *SaraWernig Zorc,Austria*
10:00 – 10:45	Keynote Lecture 2 Poverty as a “Druggable” Target: A Framework for Oncology Health Equity Research *Kira Bona, US*
10:45 – 11:15	Coffee Break
11:15 – 12:05	Parallel Session 6 Development of a neuroblastoma-specific clinically validated circulating tumor DNA assay, Grace Polkosnik, US The LIQUIDHOPE consortium (ERA-NET, TRANSCAN-2): Advancing liquid biopsies for monitoring and personalized treatment of children with neuroblastoma, Marco Lodrini, Germany Serially quantifying TERT rearrangement breakpoints in cfDNA enables minimal residual disease monitoring in patients with neuroblastoma, Jan Fredrik Hollander, Germany Nucleosome footprinting enables inference of expression profiles in circulating tumor DNA from neuroblastoma patients, Gudrun Schleiermacher, France The potential of liquid biopsies by neuroblastoma-specific adrenergic and mesenchymal mRNA panels and cell-free DNA detection, Godelieve Andrea Tytgat, Netherlands
12:05 – 14:05	Lunch Break & Poster Viewing Group B
14:05 – 15:05	*Plenary Session 4: Clinical trials* Clinicobiological treatment stratification leads to excellent prognosis in MYCN-NA disseminated NB patients ≤12 months. Results of SIOPEN-LINES trial, *Irene Jiménez, Spain* Long term infusion of dinutuximab beta is associated with a survival advantage over short term infusion. Results from the HR-NBL1/SIOPEN trial, *Holger N Lode, Germany* Complete primary tumor resection is associated with improved outcomes in patients with high-risk neuroblastoma treated on COG ANBL0532, *Christa N Grant, US* Elucidating the B cell mediated anti-tumor immune response in neuroblastoma with opsoclonus myoclonus ataxia syndrome, *Matthias Fischer, Germany*
15:05 – 15:20	Rapid Fire Session 2 MYCN overexpression biases human sympatho-adrenergic development towards progenitor cells causing neuroblastoma-like tumor xenografts, Stéphane Van Haver, US Proteomic insights into extracellular vesicles in neuroblastoma biology, *Martin Auber, Germany* Mechanisms of extracellular vesicles-mediated neuroblastoma metastasis, Vladimir S. Spiegelman, US Administration of Intracerebroventricular Dinutuximab in the Treatment of CNS Neuroblastoma and Determination of CSF Pharmacokinetics, *Michael Migotsky, US* Survival Outcomes in Patients with High-Risk Neuroblastoma on Eflornithine (DFMO) Maintenance: Matched External Control Analysis at 7-Year Follow-Up, *William Ferguson, US* Inferring the evolution of structural genomic alterations in neuroblastoma by linked-read whole-genome sequencing, *Christoph Bartenhagen, Germany* Dinutuximab administration during Induction does not increase the development of HACA during Post-Consolidation, a report from COG ANBL17P1, *Ankita Shahi, US* Potential therapeutic targets for ATRX-aberrant neuroblastoma revealed by genome-wide CRISPR-Cas9 synthetic lethality screens, *Fenja L. Fahrig, Netherlands* Functional profiling on {ex vivo} neuroblastoma models: global collaboration to drive implementation in precision medicine, *Eleonora Jacoba Looze, Netherlands* Optimized Syngeneic Neuroblastoma Models to Advance Cell Therapies, *Ying Wang, US*
15:20 – 15:50	Coffee Break
15:50 – 16:40	Parallel Session 9 MYCN Amplification Shapes Heterogeneity and Cellular State Dynamics in Neuroblastoma, Stefano Di Giulio, US Heterogeneous oncogene dosage driven by extrachromosomal DNA determines neuroblastoma response to therapy, Giulia Montuori, Italy An integrated approach to discover and target oncogenic N-myc complexes, Bo Qiu, US The USP11/USP7/TCEAL1 complex stabilizes RNAPII during early transcription to sustain oncogenic gene expression, Gabriele Büchel, Germany The immunologic impact of MYCN downregulation in neuroblastoma cells, Kyabeth M. Torres Rodriguez, US
16:40 – 18:10	Poster Session Group B
18:10 – 19:40	Young Investigator Reception

08:00 – 08:45	Sponsored Symposium 2
08:45 – 09:00	Comfort Break
09:00 – 10:00
10:00 – 10:45
10:45 – 11:15	Coffee Break
11:15 – 12:05	Parallel Session 7: Low risk NB (Clin) Clinical outcome of patients with opsoclonus-myoclonus-ataxia syndrome (OMAS) treated in the SIOPEN OMS/DES2011 study, Benoit Dumont, France Reduction of treatment burden in Low-Risk Neuroblastoma with favourable biology: Results of the SIOPEN LINES trial, *Vanessa Segura, Spain* SIOPEN LINES trial for patients with unresectable localized, MYCN non-amplified Neuroblastoma over 18 months: are really all at intermediate risk? Adela Cañete, Spain Outcomes for Patients with low stage MYCN amplified neuroblastoma (INSS stage 1, 2): A report from the International Neuroblastoma Risk Group (INRG), *Anne L Ryan, Australia* Influence of mIBG positive Residues after Surgery on Survival in Patients with MYCN amplified localized Neuroblastoma: the HR-NBL1/SIOPEN Study, *Ruth Ladenstein, Austria*
12:05 – 14:05	Lunch Break & Poster Viewing Group B
	12:45 – 13:30 Sponsored Symposium 3
	12:15 – 14:00 ANR Advisory Board Meeting
14:05 – 15:05
15:05 – 15:20
15:20 – 15:50	Coffee Break
15:50 – 16:40	Parallel Session 10: Nov tx (transl) Systemic arginine deprivation with standard-of-care chemotherapy effectively treats high-risk neuroblastoma models, Kimberley M. Hanssen, Australia RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity, *Jun Yang, US* Pre-clinical development of novel AURKA degrading PROTACs for in vivo use, Muhammad Rishfi, Belgium The polyamine transporter ATP13A3 mediates resistance to DFMO in neuroblastoma cells and can be inhibited by AMXT 1501, *Klaartje Somers, Australia* Novel drug combinations exploit metabolic vulnerabilities in neuroblastoma, *Conny Tümmler, Sweden*
16:40 – 18:10	Poster Session Group B
18:10 – 19:40	Young Investigator Reception

08:00 – 08:45	Education Session 2: Developmental Biology Isabella Janoueix-Lerosey & Laura Pahlberg
08:45 – 09:00	Comfort Break
09:00 – 09:30	Life Time Achievement Awards and 20-year Anniversary INRG
09:30 – 10:30	Plenary Session 5 Transcriptional diversity and cellular plasticity in neuroblastoma, Nora Fresmann, Germany Phenotypic Plasticity is a Heritable Trait and Drives Adaptive Evolution in Neuroblastoma, Cecilia Roux, UK Unveiling the role of MYCN and ALK oncogenes in the early stages of neuroblastoma development using genetically engineered mouse models, Nour El Houda Djerir, France Evolutionary trajectories of neuroblastoma pathogenesis, Carolina Rosswog, Germany
10:30 – 11:15	Keynote Lecture 3 Molecular and cellular mechanisms of SCLC progression and therapy response Julien Sage, US
11:15 – 12:15	Coffee Break
11:15 – 12:15	Poster Viewing Group C
11:45 – 12:35	Parallel Session 11 Neuroblastoma PDX tumors include MES-type tumor cells, Ekaterina Skorova, Germany Generation of an In Vivo lineage tracing model of neuroblastoma to reveal mechanisms of therapy resistance, Ellen M. Westerhout, Netherlands Lineage-Specific Transcription Factor Screen Identifies TFs That Regulate Neuroblastoma Plasticity and Drug Resistance, Xingyu Liu, US CACNA2D3: A Key Regulator of Phenotypic Transdifferentiation in Neuroblastoma by executing its function at RNA and protein level, Bharat Prajapati, Sweden A Genome-derived Non-coding Cell State Reporter Permits Targeting of Cellular Heterogeneity and Reprogramming of Chemoresistance, Noha AM Shendy, US
	Free Afternoon Activities
19:30	Gala Dinner

08:00 – 08:45	Education Session 2: Developmental Biology Isabella Janoueix-Lerosey & Laura Pahlberg
08:45 – 09:00	Comfort Break
09:00 – 09:30	Life Time Achievement Awards and 20-year Anniversary INRG
09:30 – 10:30	Plenary Session 5 Transcriptional diversity and cellular plasticity in neuroblastoma, Nora Fresmann, Germany Phenotypic Plasticity is a Heritable Trait and Drives Adaptive Evolution in Neuroblastoma, Cecilia Roux, UK Unveiling the role of MYCN and ALK oncogenes in the early stages of neuroblastoma development using genetically engineered mouse models, Nour El Houda Djerir, France Evolutionary trajectories of neuroblastoma pathogenesis, Carolina Rosswog, Germany
10:30 – 11:15	Keynote Lecture 3 Molecular and cellular mechanisms of SCLC progression and therapy response Julien Sage, US
11:15 – 12:15	Coffee Break
11:15 – 12:15	Poster Viewing Group C
11:45 – 12:35	Parallel Session 12 A human stem cell model of neuroblastoma reveals candidate drivers of tumorigenesis on chromosome 17q, Wanqi Fang, US A humanized In Vivo model for neuroblastoma bone metastasis, Alexandra Seger, Sweden Generation of neural crest-derived neuroblastoma models to investigate MYCN vulnerabilities, Federica Lorenzi, UK Conditional c-MYC activation in catecholaminergic cells drives distinct tumors: neuroblastoma vs somatostatinoma, Jun Yang, US A tractable immunocompetent neuroblastoma murine model for immunoncology (IO) preclinical studies, Timothy T. Spear, US
	Free Afternoon Activities
19:30	Gala Dinner

08:00 – 08:45	Sponsored Symposium 4
08:45 – 09:00	Comfort Break
09:00 – 09:30
09:30 – 10:30
10:30 – 11:15
11:15 – 12:15	Coffee Break
11:15 – 12:15	Poster Viewing Group C
11:45 – 12:35	Parallel Session 13 Genomic and Transcriptomic Profiles Following 131I-MIBG Therapy on a Phase III Clinical Trial for High-Risk Neuroblastoma, Kevin L. Ying, US The impact of mIBG therapy in first-line treatment of patients with high-risk metastatic neuroblastoma: results of the GPOH study NB2004-HR, Thorsten Simon, Germany Initial toxicity and response data from MINIVAN, a Phase 1 trial of 131-I mIBG, Nivolumab and Dinutuximab Beta in relapsed/refractory neuroblastoma, Juliet C Gray, UK 225Ac alpha particle pre-targeted radioimmunotherapy (PRIT) with wide therapeutic window against neuroblastoma, Karina Leung, US 18F-meta-fluorobenzylguanidine (mFBG) PET Imaging in High-Risk Neuroblastoma Patients, Shakeel Modak, US
	Free Afternoon Activities
19:30	Gala Dinner

08:00 – 08:45	Education Session 3: Immunology Paul Sondel & John Anderson
08:45 – 09:00	Comfort Break
09:00 – 10:00	Plenary Session 6 Single cell analysis of murine neuroblastomas reveals developmental paths defined by telomerase activity and time, Lisa Werr, Germany Somatic focally amplified super-enhancers as novel oncogenic driver in neuroblastoma, Vincenzo Aievola, Italy KAT6A/B inhibition synergizes with retinoic acid and enhances the efficacy of GD2-targeted immunotherapy in neuroblastoma, Nina Weichert Leahey, US Exploiting the 17q gain/TRIM37 overexpression with the PLK4 inhibitor RP-1664 shows potent efficacy in preclinical high-risk neuroblastoma models, Minu Samanta, US
10:00 – 10:15	Rapid Fire Session 3 Investigating the functional significance NB risk locus 6p22.3: Role of ATXN1-AS1 and NB specific super enhancer in NB development and progression, Kamali Nagarajan, Sweden Unmasking Oncogenic Drivers in Neuroblastoma Through Integrative Analysis and Functional Validation, Ryan Borchert, US A new core regulatory circuitry driving a noradrenergic to mesenchymal transition highlights YAP/TAZ as critical players of neuroblastoma plasticity, Cécile Thirant, France Evaluation of Indocyanine Green-Labeled Dinutuximab as a Novel In Vivo Molecular Imaging Agent for Neuroblastoma: an Orthotopic Murine Model, William G Lee, US Long-term outcomes of patients with relapsed/refractory neuroblastoma treated on ANBL1221: A report from the Children’s Oncology Group, Elizabeth Sokol, US Enhanced Recovery after Surgery (ERAS) improves length of stay and complications after resection of abdominal neuroblastoma, Sara A Mansfield, US FDG and FDOPA PET scans at diagnosis predict tumor behavior and gross total resection in neuroblastoma, Yen Lin Liu, Taiwan Characterization of the functional impact of G4 ligands on telomere maintenance mechanisms in high-risk neuroblastoma, Anna Borovkov, France BMP signaling determines neuroblastoma cell fate and sensitivity to retinoic acid, Min Pan, US Characterizing a panel of neuroblastoma patient-derived xenografts for response to induction and salvage chemotherapy, Min Hee Kang, US
10:15 – 11:15	Plenary Session 7 Addition of Eflornithine to Chemoimmunotherapy Does Not Improve Response Rate in Relapsed/Refractory Neuroblastoma: A Children’s Oncology Group Report, Margaret E Macy, US Anti-CD40 monoclonal antibody improves the efficacy of a current anti-GD2 chemo-immunotherapy regimen in a mouse neuroblastoma model, Alexander L Rakhmilevich, US IMiD drug regulation of CAR-T cell function and tumour environment modulation through iTAG2, a novel switch mechanism mediated by protein degradation, John Anderson, UK The super-enhancer driven nicotinic acetylcholine α3β4 receptor complex as an immunotherapeutic target in high-risk neuroblastoma, Patrick Mark Schürch, US
11:15 – 11:45	Coffee Break
11:45 – 12:35	Parallel Session 14 MYCN/Aurora-A complexes resolve transcription-replication conflicts by phosphorylating the T-loop of CDK12, Mareike Müller, Germany CDK9 Inhibition Suppresses MYCN-Driven Neuroblastoma and Enhances Immune Modulation, Evon Poon, UK The glycogen synthase kinase-3β inhibitor 9-ING-41 in combination with chemoimmunotherapy provides long-term survival in the Th-MYCN mouse model, Jayne Murray, Australia Arginine depletion via dietary or pharmacologic means potently synergizes with high-dose DFMO to reprogram translation and regress neuroblastoma, Michael D. Hogarty, US Apatinib in Combination with Irinotecan and Temozolomide for Refractory/ Relapsed Neuroblastoma (APTN-01): A Multicenter, Single-Arm, Phase 1/2 Trial, Juan Wang, China
12:35 – 14:05	Lunch Break & Poster Session Group C
11:45 – 12:35	Parallel Session 17 Establishment of neuroblastoma treatment screening platform in multi-bio-models and multi-omics, Rui Dong, China Targeting the Anaplastic Lymphoma Kinase (ALK) Oncoprotein with Novel Immunotherapeutic Platforms in Neuroblastoma and ALK-Expressing Malignancies, Alberto D Guerra, US Targeting ALK in Relapsed High-Risk Neuroblastoma: Real-World Insights from the SACHA-France Study, Pablo Berlanga, France ALK/ATR combination inhibition is effective in neuroblastoma mouse tumors driven by MYCN, Ruth Palmer, Sweden In-vitro and in-vivo analyses of resistance mechanisms to treatment combinations with ALK inhibitors in neuroblastoma, Angela Bellini, France
14:55 – 15:25	Coffee Break
15:25 – 16:10	Keynote Lecture 4 How PROTAC degraders work: Molecular recognition and design principles Alessio Ciulli, UK
16:10 – 16:35	Scientific Awards ANR 2025
16:35 – 17:00	Closing Ceremony

08:00 – 08:45	Education Session 3: Immunology Paul Sondel & John Anderson
08:45 – 09:00	Comfort Break
09:00 – 10:00	Plenary Session 6 Single cell analysis of murine neuroblastomas reveals developmental paths defined by telomerase activity and time, Lisa Werr, Germany Somatic focally amplified super-enhancers as novel oncogenic driver in neuroblastoma, Vincenzo Aievola, Italy KAT6A/B inhibition synergizes with retinoic acid and enhances the efficacy of GD2-targeted immunotherapy in neuroblastoma, Nina Weichert Leahey, US Exploiting the 17q gain/TRIM37 overexpression with the PLK4 inhibitor RP-1664 shows potent efficacy in preclinical high-risk neuroblastoma models, Minu Samanta, US
10:00 – 10:15	Rapid Fire Session 3 Investigating the functional significance NB risk locus 6p22.3: Role of ATXN1-AS1 and NB specific super enhancer in NB development and progression, Kamali Nagarajan, Sweden Unmasking Oncogenic Drivers in Neuroblastoma Through Integrative Analysis and Functional Validation, Ryan Borchert, US A new core regulatory circuitry driving a noradrenergic to mesenchymal transition highlights YAP/TAZ as critical players of neuroblastoma plasticity, Cécile Thirant, France Evaluation of Indocyanine Green-Labeled Dinutuximab as a Novel In Vivo Molecular Imaging Agent for Neuroblastoma: an Orthotopic Murine Model, William G Lee, US Long-term outcomes of patients with relapsed/refractory neuroblastoma treated on ANBL1221: A report from the Children’s Oncology Group, Elizabeth Sokol, US Enhanced Recovery after Surgery (ERAS) improves length of stay and complications after resection of abdominal neuroblastoma, Sara A Mansfield, US FDG and FDOPA PET scans at diagnosis predict tumor behavior and gross total resection in neuroblastoma, Yen Lin Liu, Taiwan Characterization of the functional impact of G4 ligands on telomere maintenance mechanisms in high-risk neuroblastoma, Anna Borovkov, France BMP signaling determines neuroblastoma cell fate and sensitivity to retinoic acid, Min Pan, US Characterizing a panel of neuroblastoma patient-derived xenografts for response to induction and salvage chemotherapy, Min Hee Kang, US
10:15 – 11:15	Plenary Session 7 Addition of Eflornithine to Chemoimmunotherapy Does Not Improve Response Rate in Relapsed/Refractory Neuroblastoma: A Children’s Oncology Group Report, Margaret E Macy, US Anti-CD40 monoclonal antibody improves the efficacy of a current anti-GD2 chemo-immunotherapy regimen in a mouse neuroblastoma model, Alexander L Rakhmilevich, US IMiD drug regulation of CAR-T cell function and tumour environment modulation through iTAG2, a novel switch mechanism mediated by protein degradation, John Anderson, UK The super-enhancer driven nicotinic acetylcholine α3β4 receptor complex as an immunotherapeutic target in high-risk neuroblastoma, Patrick Mark Schürch, US
11:15 – 11:45	Coffee Break
11:45 – 12:35	Parallel Session 14 MYCN/Aurora-A complexes resolve transcription-replication conflicts by phosphorylating the T-loop of CDK12, Mareike Müller, Germany CDK9 Inhibition Suppresses MYCN-Driven Neuroblastoma and Enhances Immune Modulation, Evon Poon, UK The glycogen synthase kinase-3β inhibitor 9-ING-41 in combination with chemoimmunotherapy provides long-term survival in the Th-MYCN mouse model, Jayne Murray, Australia Arginine depletion via dietary or pharmacologic means potently synergizes with high-dose DFMO to reprogram translation and regress neuroblastoma, Michael D. Hogarty, US Apatinib in Combination with Irinotecan and Temozolomide for Refractory/ Relapsed Neuroblastoma (APTN-01): A Multicenter, Single-Arm, Phase 1/2 Trial, Juan Wang, China
12:35 – 14:05	Lunch Break & Poster Session Group C
11:45 – 12:35	Parallel Session 17 Establishment of neuroblastoma treatment screening platform in multi-bio-models and multi-omics, Rui Dong, China Targeting the Anaplastic Lymphoma Kinase (ALK) Oncoprotein with Novel Immunotherapeutic Platforms in Neuroblastoma and ALK-Expressing Malignancies, Alberto D Guerra, US Targeting ALK in Relapsed High-Risk Neuroblastoma: Real-World Insights from the SACHA-France Study, Pablo Berlanga, France ALK/ATR combination inhibition is effective in neuroblastoma mouse tumors driven by MYCN, Ruth Palmer, Sweden In-vitro and in-vivo analyses of resistance mechanisms to treatment combinations with ALK inhibitors in neuroblastoma, Angela Bellini, France
14:55 – 15:25	Coffee Break
15:25 – 16:10	Keynote Lecture 4 How PROTAC degraders work: Molecular recognition and design principles Alessio Ciulli, UK
16:10 – 16:35	Scientific Awards ANR 2025
16:35 – 17:00	Closing Ceremony

08:00 – 08:45
08:45 – 09:00	Comfort Break
09:00 – 10:00
10:00 – 10:15
10:15 – 11:15
11:15 – 11:45	Coffee Break
11:45 – 12:35	Parallel Session 16: Epigen (basic) H3K27me3-mediated epigenetic repression regulates neuroblastoma development and contributes to biological heterogeneity, Charlotte Butterworth, France Combined PRC2 and Menin inhibition induces neuronal differentiation and GD2 expression through activation of bivalent chromatin domains, Nathaniel Mabe, US Inhibiting m6A Reader Proteins Suppresses Neuroblastoma Growth and Remodels the Tumor Microenvironment, Peng Xia, US CHAF1A Reprograms Oncogenic Transcriptional Networks to Block Neuroblastoma Differentiation and Promote Oncogenesis, Vrajesh Karkhanis, US Targeting the interplay between replication stress (RS) induced DNA damage response (DDR) and epigenetics in children with high-risk neuroblastoma, Hannah E Hartley, Australia
12:35 – 14:05	Lunch Break & Poster Session Group C
11:45 – 12:35
14:55 – 15:25	Coffee Break
15:25 – 16:10
16:10 – 16:35
16:35 – 17:00